Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer

Yuzhen Zhou; Vincent D D'Andrea; Surish P Shanmugam; Isabella Stelter; Dag R Stormoen; Rea Chroneos; Timothy Hanlon; Ilana Epstein; Raie T Bekele; William J Anderson; Filipe F L Carvalho; Joaquim Bellmunt; Kent W Mouw

doi:10.1016/j.eururo.2024.03.013

Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer

Yuzhen Zhou, Vincent D D'Andrea, Surish P Shanmugam, Isabella Stelter, Dag R Stormoen, Rea Chroneos, Timothy Hanlon, Ilana Epstein, Raie T Bekele, William J Anderson, Filipe F L Carvalho, Joaquim Bellmunt, Kent W Mouw^*

^*Corresponding author for this work

Department of Oncology

7 Citations (Scopus)

Original language	English
Journal	European Urology
Volume	86
Issue number	1
Pages (from-to)	69-71
Number of pages	3
ISSN	0302-2838
DOIs	https://doi.org/10.1016/j.eururo.2024.03.013
Publication status	Published - 2024

Keywords

Animals
Antibodies, Monoclonal, Humanized/therapeutic use
Camptothecin/analogs & derivatives
Chemoradiotherapy
Humans
Immunoconjugates
Mice
Urinary Bladder Neoplasms/drug therapy

Access to Document

10.1016/j.eururo.2024.03.013

Cite this

Zhou, Y., D'Andrea, V. D., Shanmugam, S. P., Stelter, I., Stormoen, D. R., Chroneos, R., Hanlon, T., Epstein, I., Bekele, R. T., Anderson, W. J., Carvalho, F. F. L., Bellmunt, J., & Mouw, K. W. (2024). Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer. European Urology, 86(1), 69-71. https://doi.org/10.1016/j.eururo.2024.03.013

Zhou, Y, D'Andrea, VD, Shanmugam, SP, Stelter, I, Stormoen, DR, Chroneos, R, Hanlon, T, Epstein, I, Bekele, RT, Anderson, WJ, Carvalho, FFL, Bellmunt, J & Mouw, KW 2024, 'Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer', European Urology, vol. 86, no. 1, pp. 69-71. https://doi.org/10.1016/j.eururo.2024.03.013

@article{2b28cf0295cd40db82e3660b57fb7177,

title = "Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer",

keywords = "Animals, Antibodies, Monoclonal, Humanized/therapeutic use, Camptothecin/analogs \& derivatives, Chemoradiotherapy, Humans, Immunoconjugates, Mice, Urinary Bladder Neoplasms/drug therapy",

author = "Yuzhen Zhou and D'Andrea, \{Vincent D\} and Shanmugam, \{Surish P\} and Isabella Stelter and Stormoen, \{Dag R\} and Rea Chroneos and Timothy Hanlon and Ilana Epstein and Bekele, \{Raie T\} and Anderson, \{William J\} and Carvalho, \{Filipe F L\} and Joaquim Bellmunt and Mouw, \{Kent W\}",

year = "2024",

doi = "10.1016/j.eururo.2024.03.013",

language = "English",

volume = "86",

pages = "69--71",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier BV",

number = "1",

}

TY - JOUR

T1 - Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer

AU - Zhou, Yuzhen

AU - D'Andrea, Vincent D

AU - Shanmugam, Surish P

AU - Stelter, Isabella

AU - Stormoen, Dag R

AU - Chroneos, Rea

AU - Hanlon, Timothy

AU - Epstein, Ilana

AU - Bekele, Raie T

AU - Anderson, William J

AU - Carvalho, Filipe F L

AU - Bellmunt, Joaquim

AU - Mouw, Kent W

PY - 2024

Y1 - 2024

KW - Animals

KW - Antibodies, Monoclonal, Humanized/therapeutic use

KW - Camptothecin/analogs & derivatives

KW - Chemoradiotherapy

KW - Humans

KW - Immunoconjugates

KW - Mice

KW - Urinary Bladder Neoplasms/drug therapy

UR - https://www.scopus.com/pages/publications/85189706565

U2 - 10.1016/j.eururo.2024.03.013

DO - 10.1016/j.eururo.2024.03.013

M3 - Letter

C2 - 38523005

SN - 0302-2838

VL - 86

SP - 69

EP - 71

JO - European Urology

JF - European Urology

IS - 1

ER -

Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer

Keywords

Access to Document

Other files and links

Cite this